鼻出血の世界市場 - 2025年～2032年

鼻出血の世界市場は、2024年に1億9,448万米ドルに達し、2032年には2億8,930万米ドルに達すると予測され、予測期間2025年から2032年にはCAGR 5.3%で成長すると予測されています。

一般に鼻血として知られる鼻出血は、特に耳鼻咽喉科（ENT）医療において、プライマリケアと救急の両方で遭遇する一般的な疾患です。鼻血は前方鼻血と後方鼻血の2種類に分類されます。

前鼻出血は一般的に、鼻中隔の前方に位置する血管網であるキセルバッハ神経叢（Kiesselbach's plexus）から生じます。この血管網は、主に鼻中隔に血液を供給する複数の動脈の吻合によって形成され、前鼻出血の約90％の原因となっています（鼻出血）。

鼻出血（鼻出血）は二峰性の年齢分布を示し、2～10歳の小児と50～80歳の高齢者に最も多く発症します。このパターンは、いくつかの解剖学的、生理学的、および環境的要因に起因しています。

後鼻出血は鼻腔の奥深くで起こり、鼻の奥の太い血管と関連しています。これらの出血は、後鼻腔に血液を供給する蝶形口蓋動脈の分枝に由来することが多いです。これらの要因が、世界の鼻出血市場拡大の原動力となっています。

市場力学：

促進要因と抑制要因

鼻出血の発生率の増加

世界の鼻出血市場の需要は、複数の要因によって牽引されています。主な要因の1つは、鼻出血の発生率の増加です。

鼻出血、つまり鼻血の有病率の増加は、環境条件、ライフスタイルの変化、長期的な病気による健康問題の増加など、さまざまな要因に関連している可能性があります。鼻血は、乾燥した環境、特に室内の暖房によって湿度が低下する冬季に特によく見られます。この湿度不足は鼻粘膜を乾燥させ、ひび割れさせ、血管を破裂させやすくします。したがって、こうした事態を防ぎ、鼻の健康を守るためには、適切な湿度を保つことが不可欠です。

2022年9月に発表されたNCBIの調査によると、約60％の人が一生のうちに一度は鼻血を経験するといいます。この高い有病率は、この症状が様々な年齢層でいかに日常的なものであるかを裏付けています。鼻血のうち、治療や介入を必要とするほど重篤なものは10％程度です。ほとんどのエピソードは軽度であり、専門家の助けがなくても自宅で効果的に管理できます。

相対湿度や気温などの気象学的要因は、鼻出血の発生率と有意な相関があることが調査で示されています。例えば、湿度が低いと、粘膜の刺激や乾燥による鼻血の発生が増加します。これらの要因は、鼻出血の世界市場に対する需要を引き起こしています。

同様に、2023年3月のNCBI調査研究データによると、10年間にわたって2つの病院から収集されたデータに基づき、日平均相対湿度と鼻出血、すなわち鼻血の発生率との間に有意な負の相関関係があることを強調しています。具体的には、平均相対湿度が1％上昇すると、毎日報告される鼻出血症例数が1.1％減少することがわかった。この関係から、湿度が上がると鼻血が出にくくなることが示唆されます。これらの要因が鼻出血市場を牽引しています。

さらに、業界の主な企業は、この世界の鼻出血市場の成長を促進する製品の発売や技術開発を行っています。

治療の副作用

治療の副作用は、鼻出血の世界市場の成長を妨げるでしょう。鼻出血（鼻血）では、血液の一部が喉の奥から胃に排出されるのが一般的です。出血を抑えるために、出血部位に熱や化学薬品（硝酸銀など）を加える焼灼術がしばしば行われます。効果的ではありますが、この処置は治療中および治療後にかなりの痛みや不快感を引き起こす可能性があります。

研究によると、かなりの割合の患者が焼灼後の不快感を訴えており、痛みのレベルは使用される手技によって異なります。例えば、48％もの患者が焼灼後に不快感を経験したとの研究結果もあり、将来同様の経験をすることを恐れた場合、更なる医療介入を求めることを躊躇させる可能性があります。したがって、上記のような要因が鼻出血の世界市場の潜在的成長を制限している可能性があります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 鼻出血の発生率増加
  • 抑制要因
    • 治療の副作用
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 特許分析
• 規制分析
• SWOT分析
• アンメットニーズ

第6章 タイプ別

• 前部鼻出血
• 後部鼻出血

第7章 治療の種類別

• 血管収縮薬
  • オキシメタゾリン
  • フェニレフリン
• 麻酔薬
  • コカイン
  • リドカイン
  • テトラカイン
• 抗生物質軟膏
• 焼灼剤
• 非ステロイド性抗炎症薬（NSAID）
  • イブプロフェン
  • ナプロキセン
  • アスピリン
• 鼻腔内スプレー
• 鼻腔内スプリント
• その他

第8章 流通チャネル別

• 病院薬局
• 小売薬局
• オンライン薬局

第9章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州地域
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• 中東・アフリカ

第10章 競合情勢

• 競合シナリオ
• 市況・シェア分析
• M&A分析

第11章 企業プロファイル

• Pfizer Inc.
  • 会社概要
  • 製品ポートフォリオ
    • 製品説明
    • 製品の主要業績評価指標（KPI）
    • 過去および予測の製品販売
    • 製品販売量
  • 財務概要
    • 会社の収益
    • 地域別収益分配
    • 収益予測
  • 主な発展
    • 合併と買収
    • 主な製品開発活動
    • 規制当局の承認等
  • SWOT分析
• Hemostasis, LLC
• Johnson & Johnson Services, Inc.
• GSK plc
• Alliance Pharma PLC
• Bray Group
• BANO Healthcare GmbH
• AdvaCare Pharma
• J & J DeChane

第12章 付録

The global epistaxis market reached US$ 194.48 million in 2024 and is expected to reach US$ 289.30 million by 2032, growing at a CAGR of 5.3% during the forecast period 2025-2032.

Epistaxis, commonly known as a nosebleed, is a prevalent condition encountered in both primary care and emergency settings, particularly within ear, nose, and throat (ENT) health. It can be classified into two main types: anterior epistaxis and posterior epistaxis.

Anterior nosebleeds typically arise from Kiesselbach's plexus, a network of blood vessels located in the anterior part of the nasal septum, often referred to as Little's area. This vascular network is formed by the anastomosis of several arteries, primarily supplying blood to the nasal septum, and is responsible for approximately 90% of anterior nosebleeds (epistaxis).

Nosebleeds, or epistaxis, exhibit a bimodal age distribution, most commonly affecting children aged 2 to 10 years and older adults between 50 and 80 years. This pattern can be attributed to several anatomical, physiological, and environmental factors.

Posterior nosebleeds occur deeper within the nasal cavity and are associated with larger blood vessels at the back of the nose. These bleeds often originate from branches of the sphenopalatine artery, which supplies the posterior nasal cavity. These factors have driven the global epistaxis market expansion.

Market Dynamics: Drivers & Restraints

Increasing Incidence of Epistaxis

The demand for the global epistaxis market is driven by multiple factors. One of the key factors is the increasing incidence of epistaxis.

The increasing prevalence of epistaxis, or nosebleeds, can be linked to various factors, including environmental conditions, lifestyle changes, and a rise in long-term illness health issues. Nosebleeds are particularly common in dry environments, especially during winter months when indoor heating lowers humidity levels. This lack of moisture can dry and crack the nasal mucosa, making blood vessels more prone to rupture. Thus, maintaining adequate humidity is essential to prevent these occurrences and protect nasal health.

According to an NCBI research publication in September 2022, approximately 60% of people will experience a nosebleed at some point in their lives. This high prevalence underscores how ordinary this condition is across various age groups. Only about 10% of nosebleeds are severe enough to require medical Treatment Type or intervention. Most episodes are mild and can be managed effectively at home without professional help.

Research has shown that meteorological factors such as relative humidity and temperature significantly correlate with the incidence of epistaxis. For instance, lower humidity levels are associated with increased nosebleed occurrences due to mucosal irritation and dryness. All these factors demand the global epistaxis market.

Similarly, as per NCBI research study data in March 2023, the study highlights a significant negative correlation between daily average relative humidity and the incidence of epistaxis, or nosebleeds, based on data collected from two hospitals over ten years. Specifically, it was found that a 1% increase in average relative humidity corresponds to a 1.1% decrease in the number of epistaxis cases reported daily. This relationship suggests that as humidity rises, the likelihood of experiencing nosebleeds diminishes. All these factors drive the epistaxis market.

Furthermore, key players in the industry are product launches and technological developments that would drive this global epistaxis market growth.

Side effects of treatment

The side effects of treatment will hinder the growth of the global epistaxis market. Epistaxis (nosebleeds), it is common for some blood to drain down the back of the throat into the stomach. Cauterization is often used to control bleeding by applying heat or chemicals (such as silver nitrate) to the bleeding site. While effective, this procedure can cause considerable pain and discomfort during and after the Treatment Type.

Studies indicate that a substantial percentage of patients report discomfort following cauterization, with pain levels varying based on the technique used. For instance, some studies found that up to 48% of patients experienced discomfort after cauterization, which can deter them from seeking further medical intervention if they fear similar experiences in the future. Thus, the above factors could be limiting the global epistaxis market's potential growth.

Segment Analysis

The global epistaxis market is segmented based on type, treatment type, distribution channel, and region.

Treatment Type:

The cauterizing agent's segment is expected to dominate the global epistaxis market share

The cauterizing agent segment holds a major portion of the global epistaxis market share and is expected to continue to hold a significant portion of the global epistaxis market share during the forecast period.

Cauterizing agents are chemicals that close off blood arteries by burning or scorching tissue to halt bleeding. They are crucial for preventing nasal mucosal bleeding in the case of epistaxis. The high frequency of nosebleeds and the efficacy of therapies like silver nitrate have made the cauterizing agents segment a crucial part of the global epistaxis industry. This area is predicted to remain crucial for successfully managing epistaxis as long as improvements are made and awareness is raised.

Silver nitrate and other cauterizing chemicals are accessible to both patients and healthcare professionals due to their low cost when compared to other medical procedures. Cauterization performed in outpatient settings improves patient throughput and lowers hospitalization-related medical expenses.

Silver nitrate is used topically to the bleeding site and comes in different quantities (usually 75% and 95%). By chemically coagulating tissue proteins, it effectively closes off tiny blood arteries and stops more bleeding. Because of its affordability and convenience of use, silver nitrate is preferred for treating anterior epistaxis. Healthcare workers can deliver it to patients with little discomfort, and it is commonly utilized in outpatient settings. These factors have solidified the segment's position in the global epistaxis market.

Geographical Analysis

North America is expected to hold a significant position in the global epistaxis market share

North America holds a substantial position in the global epistaxis market and is expected to hold most of the market share.

The high prevalence of epistaxis drives the market. Research suggests that almost 60% of people will get a nosebleed at some point in their lives. Due to the prevalence, there is a constant need for efficient Treatment Type alternatives, especially in emergency rooms where epistaxis is commonly treated.

In North America, the prevalence of diseases like diabetes and hypertension is rising. These diseases can be considered risk factors for epistaxis, which raises the frequency of nosebleeds in those who are afflicted. For instance, about 9.4% of the population in the United States, or 30.3 million people, have diabetes. The significance of finding efficient management methods is highlighted by the association found between epistaxis and chronic health problems.

Nosebleeds are rarely fatal, with historical data indicating that only 4 out of 2.4 million deaths in the United States. This statistic highlights the low risk associated with nosebleeds, reinforcing that while they can be distressing, they seldom lead to life-threatening situations. Furthermore, in this region, a major number of key players' presence, well-advanced healthcare infrastructure, government initiatives & regulatory support, and technological advancements, & investments would propel this market growth. Thus, the above factors are consolidating the region's position as a dominant force in the global epistaxis market.

Asia Pacific is growing at the fastest pace in the global epistaxis market share

The increasing incidence of hypertension in the Asia Pacific (APAC) region serves as a major catalyst for the growth of the epistaxis market. Hypertension-related complications have been associated with a significant number of health issues, resulting in a heightened demand for effective treatment solutions for epistaxis.

Innovations in cauterization techniques and other medical interventions have significantly improved the management of epistaxis, making treatments more effective and widely accessible. This progress has led to greater acceptance and utilization of these procedures across healthcare facilities, enhancing patient outcomes.

There is a growing recognition among healthcare professionals and patients regarding the causes and available treatment options for epistaxis. Enhanced diagnostic capabilities have also contributed to better identification of cases, thereby driving demand for various treatment products.

The aging demographic in numerous APAC countries is linked to a higher prevalence of health issues associated with epistaxis, such as chronic diseases and blood vessel fragility. This trend is expected to further expand the market size as more individuals seek treatment. Thus, the above factors are consolidating the region's position as the fastest-growing force in the global epistaxis market.

Competitive Landscape

The major global players in the epistaxis market include Pfizer Inc., Hemostasis, LLC, Johnson & Johnson Services, Inc., GSK plc, Alliance Pharma PLC, Bray Group, BANO Healthcare GmbH, AdvaCare Pharma, and J & J DeChane among others.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global epistaxis market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Type
• 3.2. Snippet by Treatment Type
• 3.3. Snippet by Distribution Channel
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing Incidence of Epistaxis
  • 4.1.2. Restraints
    • 4.1.2.1. Side Effects of Treatment
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Patent Analysis
• 5.5. Regulatory Analysis
• 5.6. SWOT Analysis
• 5.7. Unmet Needs

6. By Type

• 6.1. Introduction
  • 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Type
  • 6.1.2. Market Attractiveness Index, By Type
• 6.2. Anterior Epistaxis*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Posterior Epistaxis

7. By Treatment Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 7.1.2. Market Attractiveness Index, By Treatment Type
• 7.2. Vasoconstrictors *
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.2.3. Oxymetazoline
  • 7.2.4. Phenylephrine
• 7.3. Anesthetics
  • 7.3.1. Cocaine
  • 7.3.2. Lidocaine
  • 7.3.3. Tetracaine
• 7.4. Antibiotic Ointments
• 7.5. Cauterizing Agents
• 7.6. Nonsteroidal Anti-Inflammatories (NSAIDs)
  • 7.6.1. Ibuprofen
  • 7.6.2. Naproxen
  • 7.6.3. Aspirin
• 7.7. Intranasal Sprays
• 7.8. Intranasal Splint
• 7.9. Others

8. By Distribution Channel

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 8.1.2. Market Attractiveness Index, By Distribution Channel
• 8.2. Hospital Pharmacies*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Retail Pharmacies
• 8.4. Online Pharmacies

9. By Region

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 9.1.2. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key Region-Specific Dynamics
  • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.2.6.1. U.S.
    • 9.2.6.2. Canada
    • 9.2.6.3. Mexico
• 9.3. Europe
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
  • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.3.6.1. Germany
    • 9.3.6.2. U.K.
    • 9.3.6.3. France
    • 9.3.6.4. Spain
    • 9.3.6.5. Italy
    • 9.3.6.6. Rest of Europe
• 9.4. South America
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
  • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.4.6.1. Brazil
    • 9.4.6.2. Argentina
    • 9.4.6.3. Rest of South America
• 9.5. Asia-Pacific
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
  • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.5.6.1. China
    • 9.5.6.2. India
    • 9.5.6.3. Japan
    • 9.5.6.4. South Korea
    • 9.5.6.5. Rest of Asia-Pacific
• 9.6. Middle East and Africa
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
  • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

10. Competitive Landscape

• 10.1. Competitive Scenario
• 10.2. Market Positioning/Share Analysis
• 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

• 11.1. Pfizer Inc. *
  • 11.1.1. Company Overview
  • 11.1.2. Product Portfolio
    • 11.1.2.1. Product Description
    • 11.1.2.2. Product Key Performance Indicators (KPIs)
    • 11.1.2.3. Historic and Forecasted Product Sales
    • 11.1.2.4. Product Sales Volume
  • 11.1.3. Financial Overview
    • 11.1.3.1. Company Revenue's
    • 11.1.3.2. Geographical Revenue Shares
    • 11.1.3.3. Revenue Forecasts
  • 11.1.4. Key Developments
    • 11.1.4.1. Mergers & Acquisitions
    • 11.1.4.2. Key Product Development Activities
    • 11.1.4.3. Regulatory Approvals etc.
  • 11.1.5. SWOT Analysis
• 11.2. Hemostasis, LLC
• 11.3. Johnson & Johnson Services, Inc.
• 11.4. GSK plc
• 11.5. Alliance Pharma PLC
• 11.6. Bray Group
• 11.7. BANO Healthcare GmbH
• 11.8. AdvaCare Pharma
• 11.9. J & J DeChane

LIST NOT EXHAUSTIVE

12. Appendix

• 12.1. About Us and Services
• 12.2. Contact Us